Johnson & Johnson (NYSE:JNJ) Releases FY 2026 Earnings Guidance

Johnson & Johnson (NYSE:JNJ) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 11.050-11.150 for the period, compared to the consensus EPS estimate of 11.100. The company issued revenue guidance of $101.0 billion-$101.4 billion, compared to the consensus revenue estimate of $101.3 billion.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on JNJ. Citigroup increased their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday, October 5th. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, September 22nd. Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. TD Cowen boosted their target price on Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Scotiabank restated an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $276.22.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $14.83 on Tuesday, reaching $248.90. 16,613,205 shares of the company traded hands, compared to its average volume of 7,994,569. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The company’s 50 day moving average is $265.89 and its 200-day moving average is $249.37. The stock has a market capitalization of $599.83 billion, a PE ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The company’s revenue was up 5.9% compared to the same quarter last year. During the same period last year, the company posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts anticipate that Johnson & Johnson will post 11.18 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 87,569 shares of company stock worth $23,064,544 in the last quarter. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.